Insmed (NASDAQ:INSM) Earns Overweight Rating from Analysts at Barclays

Barclays initiated coverage on shares of Insmed (NASDAQ:INSM) in a research report report published on Tuesday, Marketbeat.com reports. The brokerage issued an overweight rating and a $231.00 target price on the biopharmaceutical company’s stock.

Several other brokerages have also weighed in on INSM. Leerink Partners reissued an “outperform” rating on shares of Insmed in a research report on Thursday, December 18th. Citigroup reiterated an “outperform” rating on shares of Insmed in a report on Thursday, December 18th. Truist Financial set a $205.00 target price on shares of Insmed in a research report on Monday, January 12th. TD Cowen set a $241.00 price target on shares of Insmed in a research report on Thursday, December 18th. Finally, Rothschild & Co Redburn assumed coverage on shares of Insmed in a research note on Thursday, December 4th. They set a “buy” rating and a $263.00 price target on the stock. Three research analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $205.83.

Insmed Trading Up 1.2%

Shares of NASDAQ:INSM opened at $157.82 on Tuesday. The company has a market cap of $33.66 billion, a PE ratio of -25.50 and a beta of 1.08. The company’s 50 day moving average is $181.08 and its two-hundred day moving average is $157.83. Insmed has a 52 week low of $60.40 and a 52 week high of $212.75. The company has a current ratio of 4.63, a quick ratio of 4.34 and a debt-to-equity ratio of 0.59.

Insmed (NASDAQ:INSM) last posted its earnings results on Thursday, October 30th. The biopharmaceutical company reported ($1.75) EPS for the quarter, missing the consensus estimate of ($1.35) by ($0.40). Insmed had a negative net margin of 264.83% and a negative return on equity of 183.55%. The business had revenue of $142.34 million during the quarter, compared to analysts’ expectations of $114.33 million. During the same period last year, the company earned ($1.27) EPS. The business’s quarterly revenue was up 52.4% compared to the same quarter last year. Equities analysts predict that Insmed will post -4.56 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, insider Orlov S. Nicole Schaeffer sold 87,290 shares of Insmed stock in a transaction that occurred on Friday, January 2nd. The shares were sold at an average price of $175.20, for a total transaction of $15,293,208.00. Following the sale, the insider owned 41,754 shares in the company, valued at $7,315,300.80. This trade represents a 67.64% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Michael Alexander Smith sold 27,130 shares of Insmed stock in a transaction on Monday, November 3rd. The stock was sold at an average price of $183.78, for a total transaction of $4,985,951.40. Following the sale, the insider directly owned 54,902 shares in the company, valued at $10,089,889.56. This trade represents a 33.07% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 296,799 shares of company stock worth $54,296,286. 3.00% of the stock is owned by company insiders.

Institutional Trading of Insmed

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. grew its stake in Insmed by 5.7% in the fourth quarter. Vanguard Group Inc. now owns 21,076,344 shares of the biopharmaceutical company’s stock worth $3,668,127,000 after purchasing an additional 1,140,524 shares in the last quarter. Darwin Global Management Ltd. raised its stake in Insmed by 5.8% during the third quarter. Darwin Global Management Ltd. now owns 20,457,445 shares of the biopharmaceutical company’s stock valued at $2,897,797,000 after buying an additional 1,112,824 shares in the last quarter. Capital International Investors lifted its holdings in Insmed by 1.0% during the 3rd quarter. Capital International Investors now owns 7,553,853 shares of the biopharmaceutical company’s stock worth $1,087,830,000 after buying an additional 74,994 shares during the last quarter. Artisan Partners Limited Partnership grew its position in shares of Insmed by 49.0% in the 3rd quarter. Artisan Partners Limited Partnership now owns 4,937,683 shares of the biopharmaceutical company’s stock worth $711,076,000 after acquiring an additional 1,623,342 shares in the last quarter. Finally, Duquesne Family Office LLC grew its position in shares of Insmed by 3.0% in the 3rd quarter. Duquesne Family Office LLC now owns 2,423,435 shares of the biopharmaceutical company’s stock worth $348,999,000 after acquiring an additional 70,000 shares in the last quarter.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.